Live
Aurobindo Pharma has received USFDA’s go ahead, for Ertapenem injection.
Ertapenem injection is a generic equivalent of Merck Sharp & Dohme Corp’s Invanz injection and the company has received approval to manufacture and market Ertapenem injection 1 g/vial.
The approved injection is used for treating moderate to severe infections caused by susceptible bacteria and is also suggested in adults for the prophylaxis of surgical site infection following elective colorectal surgery. Further, the product will be launched in July 2018.
